Physician profile
Anna Smith
NPI 1801212246
$2,182.76
in general payments reported to CMS, 2019-2025
20 companies · $801 in 2025
The $801 reported for 2025 was more than what 81% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $39.12 · 2022: $15.03 · 2023: $527 · 2024: $800 · 2025: $801.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,128.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $475.54 | 2023-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $343.54 | 2023-2025 | Verquvo, Capvaxive |
| E.R. Squibb & Sons, L.L.C. | $262.94 | 2023-2025 | Eliquis, Camzyos |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $244.24 | 2021-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $225.17 | 2023-2025 | |
| Azurity Pharmaceuticals, INC. | $127.10 | 2023-2025 | Edarbyclor, Edarbi, Edarbi |
| Bayer Healthcare Pharmaceuticals INC. | $101.90 | 2024-2025 | |
| Novo Nordisk INC | $69.64 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $59.17 | 2021-2024 | Xarelto |
| Esperion Therapeutics, INC. | $58.31 | 2023-2024 | Nexletol |
| Kiniksa Pharmaceuticals International, Plc | $32.16 | 2024 | Arcalyst |
| Pfizer INC. | $29.56 | 2025 | |
| Edwards Lifesciences Corporation | $23.17 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Atricure, INC. | $22.95 | 2025 | Synergy Ablation System |
| Kestra Medical Technology Services, INC. | $20.65 | 2024 | Assure Wcd |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $18.73 | 2023 | Farxiga |
| Bridgebio Pharma, INC. | $18.15 | 2025 | Attruby |
| Astellas Pharma US INC | $17.37 | 2021 | |
| Genzyme Corporation | $16.45 | 2023 | |
| Scpharmaceuticals INC. | $16.02 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.